Capital Advisors Inc. OK boosted its position in shares of AbbVie Inc (NYSE:ABBV) by 1.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 290,860 shares of the company’s stock after acquiring an additional 5,411 shares during the period. AbbVie makes up approximately 1.1% of Capital Advisors Inc. OK’s holdings, making the stock its 25th largest holding. Capital Advisors Inc. OK’s holdings in AbbVie were worth $26,925,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Public Employees Retirement Association of Colorado lifted its holdings in shares of AbbVie by 4.0% during the first quarter. Public Employees Retirement Association of Colorado now owns 280,474 shares of the company’s stock worth $21,369,000 after purchasing an additional 10,738 shares during the period. Premier Asset Management LLC lifted its holdings in AbbVie by 0.9% in the first quarter. Premier Asset Management LLC now owns 18,855 shares of the company’s stock valued at $1,437,000 after buying an additional 175 shares during the period. JGP Global Gestao de Recursos Ltda. acquired a new position in AbbVie in the first quarter valued at $312,000. Oakworth Capital Inc. lifted its holdings in AbbVie by 21.3% in the first quarter. Oakworth Capital Inc. now owns 9,853 shares of the company’s stock valued at $750,000 after buying an additional 1,727 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its holdings in AbbVie by 10.0% in the first quarter. Oppenheimer & Co. Inc. now owns 213,731 shares of the company’s stock valued at $16,283,000 after buying an additional 19,360 shares during the period. Hedge funds and other institutional investors own 68.23% of the company’s stock.
In related news, Vice Chairman Carlos Alban sold 53,325 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $100.00, for a total transaction of $5,332,500.00. Following the transaction, the insider now directly owns 137,899 shares in the company, valued at $13,789,900. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.09% of the stock is currently owned by insiders.
Shares of NYSE:ABBV traded up $0.42 during midday trading on Tuesday, hitting $90.91. 3,846,025 shares of the company’s stock were exchanged, compared to its average volume of 10,071,334. The company has a debt-to-equity ratio of 5.57, a current ratio of 0.86 and a quick ratio of 0.70. The stock has a 50 day moving average price of $93.82 and a 200-day moving average price of $89.39. The company has a market cap of $159.70 billion, a PE ratio of 19.43, a price-to-earnings-growth ratio of 1.44 and a beta of 0.75. AbbVie Inc has a 12 month low of $62.55 and a 12 month high of $101.28.
AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.20 by $0.14. The company had revenue of $10.43 billion during the quarter, compared to the consensus estimate of $10.14 billion. AbbVie had a net margin of 19.20% and a negative return on equity of 628.57%. The firm’s revenue for the quarter was up 26.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.26 earnings per share. On average, analysts anticipate that AbbVie Inc will post 10.46 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.18 per share. This represents a $4.72 annualized dividend and a yield of 5.19%. The ex-dividend date of this dividend is Wednesday, October 14th. AbbVie’s dividend payout ratio (DPR) is presently 52.80%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.